Recent Updates
Recently added Catalysts
VNRX Neutral Sentiment

Transcription Factor DNA analysis in plasma

Wednesday, March 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the analysis of transcription factor DNA in plasma, highlighting its potential relevance in cancer diagnostics. It references related articles and publications that explore the prognostic value of the Nu.Q® cancer test and its implications in sepsis. However, specific findings or conclusions from the analysis are not detailed.
Price reaction · baseline $3.8 (2026-03-17 close) · hit pre-market · clean, no other VNRX news in the window
day 0 close
+5.3%
day 1
0%
day 3
+8.1%

Market Sentiment Analysis

Full Press Release Details

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields
ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Nu.Q® cancer test plasma analysis cancer diagnostics sepsis
Last updated: Mar 18, 2026

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk